Welcome to LookChem.com Sign In|Join Free
  • or
1-(2-phenylmethoxy)-2-butanone is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

265664-91-3

Post Buying Request

265664-91-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

265664-91-3 Usage

Physical state

Colorless liquid

Odor

Sweet, floral

Usage

Flavoring agent in food and beverage industry

Additional uses

Synthesis of pharmaceuticals, perfumes, and other organic compounds

Chemical classification

Ketone (contains a carbonyl group bonded to two alkyl groups)

Toxicity

Relatively low toxicity

Safety

Generally regarded as safe for use in food products when used in accordance with good manufacturing practices

Check Digit Verification of cas no

The CAS Registry Mumber 265664-91-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,5,6,6 and 4 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 265664-91:
(8*2)+(7*6)+(6*5)+(5*6)+(4*6)+(3*4)+(2*9)+(1*1)=173
173 % 10 = 3
So 265664-91-3 is a valid CAS Registry Number.

265664-91-3Relevant academic research and scientific papers

Palladium(II)-Catalyzed C(sp 3)-H Activation of N,O-Ketals towards a Method for the β-Functionalization of Ketones

Ho, Danny K.H.,Calleja, Jonas,Gaunt, Matthew J.

supporting information, p. 454 - 458 (2019/02/26)

A method for the formal β-functionalization of aliphatic ketones via a palladium-catalyzed sp 3 C-H activation pathway is reported. An N,O-ketal directs an aliphatic C-H carbonylation to form γ-lactams which upon hydrolysis generate γ-keto carb

General, Simple, and Chemoselective Catalysts for the Isomerization of Allylic Alcohols: The Importance of the Halide Ligand

Erbing, Elis,Vázquez-Romero, Ana,Bermejo Gómez, Antonio,Platero-Prats, Ana E.,Carson, Fabian,Zou, Xiaodong,Tolstoy, P?ivi,Martín-Matute, Belén

supporting information, p. 15659 - 15663 (2016/10/25)

Remarkably simple IrIIIcatalysts enable the isomerization of primary and sec-allylic alcohols under very mild reaction conditions. X-ray absorption spectroscopy (XAS) and mass spectrometry (MS) studies indicate that the catalysts, with the general formula [Cp*IrIII], require a halide ligand for catalytic activity, but no additives or additional ligands are needed.

Simple and convenient access to α,α,α-trisubstituted amides by double addition of Grignard reagents to acyl cyanohydrins

Boukattaya, Fatma,Stanovych, Andrii,Setzer, Paul,Abid, Souhir,Ammar, Houcine,Pearson-Long, Morwenna S. M.,Bertus, Philippe

body text, p. 8655 - 8657 (2012/10/08)

The double addition of Grignard (alkyl, aryl, alkenyl, alkynyl) reagents to acyl cyanohydrins was performed under unusually smooth conditions with a concomitant O-N acyl transfer, providing a very simple and general access to α,α,α-trisubstituted amides.

Copper(I)-catalyzed asymmetric desymmetrization: Synthesis of five-membered-ring compounds containing all-carbon quaternary stereocenters

Aikawa, Kohsuke,Okamoto, Tatsuya,Mikami, Koichi

, p. 10329 - 10332 (2012/07/30)

A highly stereoselective catalytic alkylation sequence for the synthesis of highly functionalized and versatile five-membered-ring compounds bearing all-carbon quaternary stereocenters was developed. Enantioselective desymmetrization of achiral cyclopentene-1,3-diones was thus executed by chiral Cu-phosphoramidite catalysts. A variety of complicated cyclopentane derivatives can be synthesized with excellent stereoselectivities using a low catalyst loading in a one-pot operation.

SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

-

, (2008/06/13)

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them. The present invention is also directed to the use of these inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 265664-91-3